Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan
- PMID: 8012971
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan
Abstract
Previous investigations have revealed that the human TE-671 MR human rhabdomyosarcoma xenograft selected in vivo for melphalan resistance (M. C. Rosenberg, et al., Cancer Res., 49: 6917-6922, 1989) is cross-resistant to a wide variety of alkylating agents and to bleomycin, but is collaterally sensitive to etoposide. Although glutathione levels were noted to be elevated in TE-671 MR compared to the melphalan-sensitive parental TE-671 xenograft, treatment with buthionine sulfoximine to deplete glutathione levels did not fully restore melphalan sensitivity in the TE-671 MR xenograft. The present studies were undertaken to search for additional mechanisms of resistance in the TE-671 MR xenograft. Drug sensitivity testing performed at the dose of agents that was lethal to 10% of the animals revealed that the TE-671 MR xenograft maintained resistance to the bifunctional cross-linking agent 1,3-bis(2-chloroethyl)-1-nitrosourea and was cross-resistant to the topoisomerase I poison topotecan. Treatment with buthionine sulfoximine did not sensitize the TE-671 MR xenograft to 1,3-bis(2-chloroethyl)-1-nitrosourea. Further, even though O6-alkylguanine-DNA alkyltransferase levels were high in both the TE-671 and TE-671 MR xenografts, depletion of O6-alkylguanine-DNA alkyltransferase activity by treatment with O6-benzylguanine substantially sensitized the TE-671 xenografts but not the TE-671 MR xenografts, suggesting an additional mechanism of resistance. Measurement of additional enzyme activities that might be involved in DNA repair revealed significant elevations in DNA polymerase alpha (46 +/- 8 (SD) units/mg protein in TE-671, 69 +/- 6 units/mg protein in TE-671 MR, P < 0.05) and DNA polymerase beta (0.43 +/- 0.01 units/mg protein in TE-671, 0.78 +/- 0.12 units/mg protein in TE-671 MR, P < 0.05) but not DNA polymerase delta or total DNA ligase. Examination of topoisomerases by activity assays and Western blotting revealed a 2-fold increase in topoisomerase II and a 2-fold decrease in topoisomerase I in the TE-671 MR xenograft compared to the parental xenograft, apparently explaining the collateral sensitivity to etoposide and cross-resistance to topotecan. These results suggest that TE-671 MR xenografts contain multiple changes in activities of DNA repair-related proteins and other nuclear proteins that could contribute to alkylating agent resistance.
Similar articles
-
Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR.Cancer Res. 1991 Aug 1;51(15):3906-9. Cancer Res. 1991. PMID: 1855207
-
Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.Cancer Res. 1989 Dec 15;49(24 Pt 1):6917-22. Cancer Res. 1989. PMID: 2582434
-
Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.Radiat Res. 1992 Feb;129(2):218-23. Radiat Res. 1992. PMID: 1734453
-
[Poisons of DNA topoisomerases I and II].Bull Cancer. 1993 Nov;80(11):923-54. Bull Cancer. 1993. PMID: 8081034 Review. French.
-
Heat shock proteins: role in thermotolerance, drug resistance, and relationship to DNA topoisomerases.NCI Monogr. 1987;(4):99-103. NCI Monogr. 1987. PMID: 2819740 Review.
Cited by
-
Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT).Br J Cancer. 2000 Jul;83(2):267-9. doi: 10.1054/bjoc.2000.1240. Br J Cancer. 2000. PMID: 10901381 Free PMC article.
-
Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.Br J Cancer. 1995 Aug;72(2):399-404. doi: 10.1038/bjc.1995.345. Br J Cancer. 1995. PMID: 7640225 Free PMC article.
-
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.Gynecol Oncol. 2012 Feb;124(2):210-5. doi: 10.1016/j.ygyno.2011.10.002. Epub 2011 Nov 1. Gynecol Oncol. 2012. PMID: 22047770 Free PMC article. Clinical Trial.
-
Mechanism of polyoxometalate-mediated inactivation of DNA polymerases: an analysis with HIV-1 reverse transcriptase indicates specificity for the DNA-binding cleft.Biochem J. 1996 Oct 15;319 ( Pt 2)(Pt 2):619-26. doi: 10.1042/bj3190619. Biochem J. 1996. PMID: 8912703 Free PMC article.
-
Single Nuclear RNA Sequencing Highlights Intra-Tumoral Heterogeneity and Tumor Microenvironment Complexity in Testicular Embryonic Rhabdomyosarcoma.J Inflamm Res. 2022 Jan 22;15:493-507. doi: 10.2147/JIR.S343068. eCollection 2022. J Inflamm Res. 2022. PMID: 35095281 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Miscellaneous